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Abstract
The inhibition of vascular endothelial growth factor receptor-3 (VEGFR-3) signaling has important
implications in circumventing tumor angiogenesis and lymphangiogenesis. Monoclonal antibodies
inhibiting ligand binding to its receptor are already in clinical trials, and a murine antibody targeted
towards the dimerization domain of the receptor has recently been described. This paves the way
for new targeting modalities for counteracting receptor dimerization and activation, but human
antibodies have thus far not been reported.
We sought to generate novel human Fab antibody fragments targeted towards the dimerization
domain of VEGFR-3, by surveying the artificial human Fab phage display library (size ~ 3 x 1010)
through affinity selections with the antigens b-R3D45 (biotinylated domains 4 and 5 of VEGFR-3)
and R3D17 (full length extracellular domain of VEGFR-3) in mobile and solid phase panning
respectively.
After 4 to 5 rounds of affinity selection, significant enrichment of VEGFR-3-specific clones was
achieved, and subsequent characterization revealed at least 11 promising novel human Fab
candidates. These Fabs were expressed in bacterial expression systems and validated by
immunoblotting. Future work may be directed towards their purification and assessment in
functional assays, such as the inhibition of ligand-mediated cell survival.
In conclusion, this study has demonstrated the robustness of the antibody library in generating
novel human Fabs against the VEGFR-3 dimerization interface that could be translated towards
the clinical inhibition of pathological angiogenesis and lymphangiogenesis in tumors.
Keywords
VEGFR-3, antibody phage display, tumor angiogenesis and lymphangiogenesis
Where deposited
Additional information
1Phage Display Selection of Antibody Fragments targeted
to VEGFR-3 Dimerization Domain
Yoke Seng Lee
Master’s Thesis
Master’s Degree in Translational Medicine
Faculty of Medicine
University of Helsinki
2014
2CONTENTS
ABBREVIATIONS ………………………………………………………………………………………………………………………………………… 4
1. INTRODUCTION and REVIEW OF THE LITERATURE ………………………………………………………………………………… 5
      1.1 Phage Display ………………………………………………………………………………………………………………………………… 5
            1.1.1 History of phage display and its development ………………………………………………………………………… 5
            1.1.2 Biology of the filamentous bacteriophage M13 ……………………………………………………………………… 6
            1.1.3 Concept of phage display ………………………………………………………………………………………………………… 6
            1.1.4 Phage display formats …..............................................................................................................  8
      1.2 Antibodies and the human Fab antibody library F-Library …………………………………………………………….. 10
            1.2.1 Antibody structure and domains …………………………………………………………………………………………… 10
            1.2.2 Description and design of the human Fab antibody library F-Library …………………………………….. 11
      1.3 VEGF signaling and its implication in tumor angiogenesis and lymphangiogenesis ………………………… 12
            1.3.1 Vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs) …………………………… 12
            1.3.2 VEGF/VEGFR signaling and the tumor vasculature ………………………………………………………………… 14
            1.3.3 The use of antibodies targeting the VEGF/VEGFR axis …………………………………………………………… 14
      1.4 Background of this Master’s thesis ……………………………………………………………………………………………….. 18
2. AIM OF THE STUDY ………………………………………………………………………………………………………………………………. 19
3. MATERIALS AND METHODS ………………………………………………………………………………………………………………….. 20
      3.1 Refreshment of antibody phage display library (F-library) …………………………………………………………….. 20
      3.2 Determination of phage infectious titer ………………………………………………………………………………………… 20
      3.3 Affinity selection with VEGFR-3 fragments ……………………………………………………………………………………. 21
      3.4 Screening for positive clones by monoclonal phage ELISA …………………………………………………………….. 22
      3.5 Cloning of VEGFR3-specific Fab genes into pET12a expression vector …………………………………………… 23
      3.6 Bacterial expression of human Fab antibody fragments ………………………………………………………………… 24
      3.7 Western blot validation of expressed anti-VEGFR3 human Fabs ……………………………………………………. 24
34. RESULTS ……………………………………………………………………………………………………………………………………………….. 25
      4.1 Affinity selection …………………………………………………………………………………………………………………………… 25
            4.1.1 Results of first series (P-series) of affinity selection experiments using b-R3D45 …………………… 25
            4.1.2 Results of second series (Q-series) of affinity selection experiments …………………………………….. 26
      4.2 Screening for positive clones by monoclonal phage ELISA and analysis by sequencing …………………. 28
            4.2.1 Characterization of clones after P-series of affinity selections ………………………………………………. 28
            4.2.2 Characterization of clones after Q-series of affinity selections ……………………………………………… 31
      4.3 Cloning of selected antibody genes into pET12a expression vector ………………………………………………. 33
      4.4 Validation of expressed human Fabs by Western blot …………………………………………………………………… 34
5. DISCUSSION …………………………………………………………………………………………………………………………………………. 36
      5.1 Selection of VEGFR-3 dimerization domain-specific Fabs and their characteristics ………………………… 36
      5.2 Modulation of the affinity selection strategy ………………………………………………………………………………… 38
      5.3 Bacterial expression of human VEGFR-3-specific Fabs …………………………………………………………………… 39
      5.4 Future prospects …………………………………………………………………………………………………………………………… 39
            5.4.1 Further development and characterization of the selected VEGFR-3 Fabs ……………………………. 39
            5.4.2 Phage display in relation to VEGF/VEGFR drug discovery in the future …………………………………. 40
6. CONCLUSION ………………………………………………………………………………………………………………………………………… 42
7. ACKNOWLEDGEMENTS ………………………………………………………………………………………………………………………… 43
REFERENCES …………………………………………………………………………………………………………………………………………….. 44
APPENDIX ………………………………………………………………………………………………………………………………………………… 49
4ABBREVIATIONS
b-R3D45 Biotinylated VEGFR-3 domains 4 and 5
BEC Blood vascular endothelial cell
CDR Complementarity determining region
CDR-Hn (where n = 1, 2 or 3) Heavy chain CDR 1, 2 or 3
CDR-L3 Light chain CDR 3
CFU Colony-forming unit
ELISA Enzyme-linked immunosorbent assay
Fab Antigen-binding antibody fragment
HAMA Human anti-mouse antibody
HUVEC Human umbilical vein endothelial cell
IPTG Isopropyl-beta-D-thiogalactopyranoside
LEC Lymphatic endothelial cell
MOI Multiplicity of infection
OD Optical density
PBS Phosphate buffered saline
PBST PBS containing Tween-20
Phage Bacteriophage
R3D17 VEGFR-3 full length extracellular domain
VEGF Vascular endothelial growth factor
VEGFR VEGF receptor
2E11 Murine monoclonal antibody against VEGFR-3 dimerization
domain
51. INTRODUCTION and REVIEW OF THE LITERATURE
1.1 Phage Display
1.1.1 History of phage display and its development
Phage display  is  a  methodology that  was first  described by George P.  Smith in  1985 in  the
prestigious journal Science. Its humble beginnings transpired with the exogenous expression of a small
peptide fragment of the EcoRI restriction endonuclease on the surface of virions – filamentous
bacteriophages which were then regarded as novel expression vectors (Smith, 1985). Though confined to
the expression of small peptides in the early years, the first antibody phage display was reported just 5
years after the technique was first introduced (McCafferty, Griffiths, Winter, & Chiswell, 1990). Since then,
its use has burgeoned into the generation and selection of large peptide and antibody libraries, where such
phages could be exploited to display an immense array of different peptides, to the order of 1011. Such
advances make it plausible and attractive to generate artificial antibody repertoires and diversity beyond
what our natural immune repertoire could achieve (Sidhu & Koide, 2007). In addition, phage display has
proven to be a robust method of surveying binding interactions against a diverse array of selector antigens,
and selected phage-displayed biomolecules assume numerous forms, including the likes of zinc finger
proteins  (Choo  &  Klug,  1994),  Src-homology-3  (SH3)  domains  (Hiipakka,  Poikonen,  &  Saksela,  1999),
hormones (Bass, Greene, & Wells, 1990)and enzymes (Demartis et al., 1999).
Antibody phage display, which exploits the bacteria Escherichia coli (E.coli) in the production
of recombinant antibodies, serves as an enticing alternative to the traditional and laborious hybridoma
technology of monoclonal antibody production. Indeed, an added advantage of using phage display as a
choice method for antibody generation is the isolation of human antibodies that circumvent problems with
immunogenicity such as hypersensitivity reactions and the elicitation of human anti-mouse antibodies
(HAMAs) (Miersch & Sidhu, 2012). One of the early successes of antibody phage display is exemplified by
the drug Adalimumab (HUMIRA), the first fully human phage display-derived monoclonal antibody, which
has been used in the clinics to inhibit the inflammatory cytokine tumor necrosis factor-α (TNF-α) in
autoimmune disorders such as rheumatoid arthritis and Crohn’s disease (Lorenz, 2002).
61.1.2 Biology of the filamentous bacteriophage M13
The M13 filamentous bacteriophage belongs to a group of closely related phages known as
the Ff phages, hence called because of their characteristic of being F pilus-specific, which also include the f1
and fd phages (Rakonjac, Bennett, Spagnuolo, Gagic, & Russel, 2011). The M13 is shaped like a cylinder, and
carries a single-stranded DNA (ssDNA) genome of about 6400 base pairs encompassing 11 genes in total. It
infects specifically male E.coli which possess the F-pilus, encoded by the F-plasmid, and this interaction,
though not completely understood, is known to be mediated by pIII, the minor coat protein of the virus. pIII
is made up of two N-terminal domains N1 and N2 and a C-terminal CT domain, and is also required for the
release of newly assembled phage progeny. The critical primary step entails the binding of N2 to the F-pilus,
resulting in pilus retraction that facilitates the ensuing binding between N1 and the host cell periplasmic
receptor TolA. The viral genome is then injected into the host cytoplasm, and the host inner membrane is
inserted with the viral coat proteins. The CT domain mediates the release of progeny virus from the host
membrane (Carmen & Jermutus, 2002). Interestingly, minute quantities of the f1 phage pIII have been
demonstrated to inhibit further viral entry due to disruption in the host membrane integrity and the F-pilus
(Boeke, Model, & Zinder, 1982). These phages differ from bacteriophages such as λ and T7 which replicate
and assemble progeny viruses in the host cell cytoplasm, releasing them as part of their lytic life cycle. On
the contrary, filamentous bacteriophages do not lyse their host cell upon replication and assembly,
therefore allowing the host and the ‘hijacker’ to thrive and propagate, consequently enabling high viral
titers to be achieved.
1.1.3 Concept of phage display
The fundamental principle of phage display is the linkage of phenotype and genotype, where
the displayed fusion protein (phenotype) is coupled to the encoding genetic information (genotype) within
a single phage particle, and as such, the genetic information that confers a target-selected interaction can
be easily decoded. Fig. 1 below illustrates the entire phage display process, where unique phages are coded
in red, blue and yellow. In brief, the golden rule of phage display involves binding – washing – eluting – and
amplification. First, a library of phages each expressing a different unique molecular signature is introduced
to a selector antigen either immobilized onto a surface or present in solution phase. Next, antigen-captured
phages are separated from nonspecific phages by washing to remove the unbound phages, followed by the
elution of the bound phages which are then used to transduce E.coli to amplify the phage population, at
which point would have been enriched with target-specific clones. The process is cycled over a few times
until the desired enrichment is attained, at the end of which specific clones could be isolated for further
analysis. The M13KO7 helper phage is used for the rescue of phage progeny and amplification of phagemid-
bearing clones (refer to below, section 1.1.4).
7Figure 1. Principle of phage display.
The entire cycle of phage display is illustrated. A library of phages each displaying a unique peptide (and
bearing its corresponding unique genome) is introduced onto a selector antigen. Following binding to the
antigen, nonspecific clones are removed by washing and specific clones are eluted for transduction of
bacteria and amplification of the phage pool, aided by helper phage co-infection. The amplified population,
now enriched with antigen-specific clones, is now subjected to the next round of selection. The process
continues until desired enrichment is observed.
Source: http://utminers.utep.edu/rwebb/html/phage_display_libraries.html.
81.1.4 Phage display formats
The two different formats of phage display are phages and phagemids, as illustrated by Fig. 2
below. Phage formats are generated by direct manipulation of the phage genome (phage vector) such that
gene of interest is fused to the genetic information encoding a phage coat protein, resulting in the
expression of fusion protein. Because all copies of the phage coat protein are expressed as fusion proteins,
this provides a multivalent display of the exogenous peptide (Lee, Iorno, Sierro, & Christ, 2007).
Phagemids, on the other hand, are phage-derived plasmid vectors of approximately 4.6
kilobases (kb) which contain key elements such as the replication origin of a plasmid, a selectable marker of
antibiotic resistance, a phage coat protein gene upstream of which the foreign gene is cloned, a promoter
region, a signal sequence, restriction enzyme sites and an intergenic region (IG). The IG region carries the
packaging sequence. An obligate requirement of phagemid vectors in producing infectious progeny phage
particles is the co-infection of helper phage such as M13KO7 and VCSM13. The helper phage contributes
the necessary genetic information to direct phage assembly and replication, though having itself carry a
modified IG region and hence subjected to less efficient replication and packaging as compared to the
phagemid which bears the wild-type IG region (Carmen & Jermutus, 2002). Importantly, this upholds the
integrity of the genotype-phenotype linkage, because the genetic blueprint (phagemid genome) that
specifies the selected target behaviour (displayed peptide) is not lost upon amplification in subsequent
rounds of selection.
The phagemid format is more common due to several reasons rendering it superior to the
phage format. First, the smaller size of the phagemid genome allows it to harbor a larger exogenous gene
of  interest.  Second,  for  the  same  reason  of  having  a  smaller  size,  it  exhibits  a  higher  transformation
efficiency consequently allowing the generation of libraries with large diversities. Third, its genome is more
stable even upon subsequent cycles of amplification. Also, DNA manipulation is facilitated through the
presence of numerous restriction sites in the phagemid genome. Last, elements such as the LacZ promoter
within the phagemid genome also offer tight control over the expression of recombinant proteins, which
may for example inhibit superinfection (Qi, Lu, Qiu, Petrenko, & Liu, 2012).
Both phage display formats require the fusion of the peptide of interest to a phage coat
protein, usually the gene VIII-encoded major coat protein pVIII or the gene III-encoded minor coat protein
pIII. In the phagemid format, particularly with pIII-fusions, a monovalent (single-copy) display of the fusion
protein is most prevalent, with the majority of the pIII proteins (approximately 5 copies in total) being wild
type and contributed by the helper phage. Therefore, the pIII-fusion phagemid system is tailored for
probing high-affinity selections while phage formats and even the pVIII-fusion phagemid system are more
adapted towards probing interactions relating to weak to moderate affinities, due to multivalent display
9and the contribution of the avidity effect (there are about 2,700 copies of the pVIII major coat protein in a
single phage particle) (Qi et al., 2012). Because of the limitations of pVIII fusions in expressing larger
proteins (Iannolo, Minenkova, Petruzzelli, & Cesareni, 1995), pIII fusions are more suited for display of
antibody fragments, as in the case of the work described herein.
Figure 2. Phage and phagemid display formats.
Fusion of the antibody gene (shown in red) to the phage gene III (shown in green and yellow) encoding the
minor coat protein pIII is used as the model for illustration. (A) A classical multivalent phage display format
where the antibody gene is directly engineered into the phage genome. (B) A modified phage display
format which contains an extra copy of the genetic information that encodes the pIII protein, therefore
capable of encoding both wild type pIII and pIII fusion proteins. This allows for the display of the fusion
protein over a range of valencies. (C) A typical phagemid display format that only encodes pIII fusion
proteins. All other phage genes encoding structural elements required for phage assembly as well as the
information encoding wild type pIII are provided by the helper phage. This results in predominantly
monovalent display of the fusion protein, although multivalent display is possible. (D) A modified version of
the phagemid display format where the phagemid encodes pIII fusion proteins while the helper phage
confers the genetic information for all other phage genes except for that encoding the wild type pIII,
therefore resulting in multivalent display. Source: (Miersch & Sidhu, 2012).
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1.2 Antibodies and the human Fab antibody library F-Library
1.2.1 Antibody structure and domains
The antibody structure and its various domains are illustrated in Fig. 3 below, using an
immunoglobulin G (IgG) molecule as a model. An antibody is constituted by 2 heavy chains (shown in blue)
and 2 light chains (shown in green) and presents with 2 identical antigen-binding sites on its ‘arms’ (one on
each arm), hence being regarded as a bivalent molecule. Fabs are antibody fragments comprised of the
antibody heavy chain N-terminal domains VH-CH1 and  the  entire  light  chain  VL-CL. These fragments can
assemble independent of the whole IgG molecule and are known to exhibit higher stability than smaller
antibody fragments such as the single-chain variable fragment (scFv) (Sidhu & Koide, 2007), which consists
of the variable domains of the heavy and light chains joint together via a peptide linker. The utility of scFvs
in phage display is compromised as these fragments are often plagued with problems with multimerization
and aggregation (Ponsel, Neugebauer, Ladetzki-Baehs, & Tissot, 2011). Within the variable domains of the
Fab (and also in scFv), there are in total 6 complementarity determining regions (CDRs), hypervariable loops
that govern antigen recognition and specificity, 3 of which are present in the heavy chain and the other 3
present in the light chain (shown in red).
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Figure 3. Antibody structure and domains.
The whole IgG molecule is represented, assembled from 2 heavy chains shown in blue and 2 light chains
shown in green. The Fab is the fragment consisting of an entire light chain and the heavy chain VH-CH1
domains; while the scFv presents with only the variable domains of the heavy and light chains connected
via a peptide linker. The VH represents a further minimalistic domain comprised only of the variable domain
of a heavy chain. Source: (Miersch & Sidhu, 2012).
1.2.2 Description and design of the human Fab antibody library F-Library
The human Fab antibody library F-Library used in our selection experiments has previously
been generated and reported in as Library D, which had the greatest randomization profile and largest
diversity (complexity) (Fellouse et al., 2007). This library has been used successfully in isolating antibodies
specific to a diverse range of antigens, including human vascular endothelial growth factor hVEGF, the
extracellular domain of prolactin receptor and 13 other protein antigens from the Midwest Center for
Structural Genomics (MCSG), demonstrating its robustness and repertoire. The library has been
constructed with the humanized Fab 4D5 as a scaffold, in a progressive fashion based on a synthetic
minimalistic design such that the heavy chain CDRs and the third CDR of the light chain (CDR-L3) are
restricted to a binary amino acid code between the residues Tyr (Y) and Ser (S) (Fellouse et al., 2005), with
each step introducing added diversity. Fig. 4 below shows the library design and CDR diversity. Non-
paratope positions (shown in orange) are subjected to randomization with a limited array of amino acid
choices (between 2 or 4 amino acids) commonly observed at such positions with natural-occurring
antibodies; while positions that are shown in grey are not randomized (often buried residues). Positions
highlighted in blue are randomized with loops containing varying number of residues, therefore providing
chemical diversity that significantly augments the library repertoire.
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Figure 4. Library Design and CDR diversity.
Randomization at the complementarity determining regions (CDRs) are shown for CDR-L3, -H1, -H2 and -
H3, with the humanized Fab 4D5 as the scaffold. Amino acids allowed at each position are represented by
their  single-letter  code.  Positions  marked  X  allows  for  any  of  the  20  genetically  encoded  amino  acids
excluding Cys. Positions highlighted in grey are invariant; whereas positions highlighted in orange represent
non-paratope positions where randomization is restricted to any of 2 or 4 amino acid choices. Positions
highlighted in blue are randomized with loops containing different lengths of residues (4-6 residues for
CDR-L3 and 6-17 residues for CDR-H3). The figure is adapted and modified from already published work
(Fellouse et al., 2007); while the nomenclature of the CDR positions is based on the description by Kabat et
al.
1.3 Vascular endothelial growth factor (VEGF) signaling and its implication in tumor angiogenesis
and lymphangiogenesis
1.3.1 Vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs)
Vascular endothelial growth factors (VEGFs) belong to a family of growth factors which in
humans consists of VEGF (VEGF-A), VEGF-B, VEGF-C, VEGF-D and placental growth factor PlGF. These
growth factors play important roles in angiogenesis, lymphangiogenesis and vasculogenesis, and are
implicated both in normal physiology and disease (Roskoski, 2007). Angiogenesis is defined as the
formation of new blood vessels from preexisting vasculature, through the process of capillary sprouting;
whereas vasculogenesis describes the process of new blood vessel formation from endothelial cells derived
from precursor hemangioblasts. Although these two processes are distinct from each other, they are both
tightly regulated by mechanisms which involve more than one signaling pathway, encompassing
VEGF/VEGF receptor (VEGFR) signaling, angiopoietin/Tie signaling (Eklund & Olsen, 2006) and Eph/Ephrin
signaling (Heroult, Schaffner, & Augustin, 2006). Lymphangiogenesis, a closely related process, refers to the
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growth of the lymphatic vasculature, and is implicated in tumor progression where tumor cells are
disseminated to regional lymph nodes and metastasized to distant sites, as well as lymphedema and other
inflammatory disorders.
In adult humans, the vasculature is normally quiescent, with the endothelial cells dividing
less than once per decade. Angiogenesis is only transiently activated upon physiological conditions such as
wound healing and during the female reproductive cycle. However, in tumor progression, this otherwise
quiescent nature becomes corrupted, and angiogenesis is continuously activated, constituting an
‘angiogenic switch’ that supports continuous vessel sprouting (Hanahan & Folkman, 1996).
VEGF, discovered in the 1980s, is a master regulator of vasculogenesis and angiogenesis,
important in early embryonic development and in adulthood. It exerts mitogenic influence and confers
survival towards vascular endothelial cells (Roskoski, 2007), as well as enhances endothelial cell and
monocyte motility (Clauss et al.,  1990). The biology of VEGF-B, on the other hand, is less well understood
and has been considered to be required for normal heart development, although interestingly it may be
involved in energy metabolism. VEGF-C and VEGF-D are predominantly factors involved in
lymphangiogenesis, although they may also contribute towards angiogenesis under certain conditions. Both
VEGF-C and VEGF-D are products of proteolytic cleavage, as opposed to VEGF and VEGF-B whose isoforms
are  derived  from  alternative  splicing  (Tammela,  Enholm,  Alitalo,  &  Paavonen,  2005). Vegfc-null mice are
embryonic lethal due to defects in the early stages of lymphatic development; while a heterozygous
disruption of the gene resulted in lymphatic deficiency and lymphedema despite survival till birth
(Karkkainen et al., 2004).
VEGF receptors (VEGFRs) belong to a family of receptors that include VEGFR-1 (Flt-1), VEGFR-
2 (KDR) and VEGFR-3 (Flt-4) protein receptor tyrosine kinases; and neuropilin-1 and neuropilin-2 non-
protein kinase co-receptors (Roskoski, 2008). The VEGF ligand mediates its function via VEGFR-1 and
VEGFR-2 (Hicklin  et  al.,  2001).  The importance of  VEGFR-1 has  already been demonstrated more than 15
years ago where germline Vegfr-1 deletion resulted in embryonic lethality due to aberrant vascular
development, although interestingly inactivation of the same receptor by deletion of the tyrosine kinase
domain still supported embryonic angiogenesis (Hiratsuka, Minowa, Kuno, Noda, & Shibuya, 1998). In
normal physiology, VEGFR-2 stimulation drives angiogenesis of blood vascular endothelial cells (BECs) while
VEGFR-3 stimulation drives that for lymphatic endothelial cells (LECs). The expression of VEGFRs by BECs
and LECs is differential, with VEGFR-1 and VEGFR-2 expressed by the former, and VEGFR-2 and VEGFR-3 by
the latter (Jeltsch, Leppanen, Saharinen, & Alitalo, 2013).
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1.3.2 VEGF/VEGFR signaling and the tumor vasculature
VEGFs have been demonstrated to promote angiogenesis and lymphangiogenesis by the
activation of VEGF receptor tyrosine kinases. Ligand binding primes the dimerization of VEGF receptor
tyrosine kinases, which become activated via transphosphorylation (Lemmon & Schlessinger, 2010). VEGF-C
ligand binding induces the heterodimerization of VEGFR-3 with VEGFR-2 in LECs, characterized by a
phosphorylation profile that is distinct from receptor homodimerization (Dixelius et al., 2003). VEGF-C-
mediated VEGFR-3 activation has also been demonstrated to enable LECs to survive, migrate and
proliferate, via downstream signaling that implicates the phosphorylation of serine kinases Akt and Erk
(Makinen et al., 2001).
VEGFR-3 is expressed during development in all endothelia of the vasculature, however in
adults its expression becomes confined to the lymphatics (Kaipainen et al., 1995). Pathological expression
of this receptor has also been observed in the tumor blood vasculature. The importance of VEGFR-3 has
already been brought to attention in an early study wherein mice deficient in this receptor are non-viable
and suffered from cardiovascular failure by embryonic day 9.5, a result of abnormalities in blood vessel
organization (Dumont et al., 1998). Previous studies have demonstrated in murine models of angiogenesis
that the inhibition of VEGFR-3 signaling by monoclonal antibodies suppressed endothelial proliferation,
sprouting and vessel branching. In addition, the combinatorial use of VEGFR-3 and VEGFR-2 antibodies
complemented each other and reported an augmented inhibition of angiogenesis and tumor growth
(Tammela et al., 2008). VEGFR-3 is activated by the ligands VEGF-C and VEGF-D, and soluble ligand traps
that take the form of the soluble extracellular domain of the receptor have also been successfully
employed to disrupt VEGFR-3 signaling and inhibit tumor lymphangiogenesis and metastatic dissemination
to regional lymph nodes in a prostate cancer xenograft model (Burton et al., 2008).
1.3.3 The use of antibodies targeting the VEGF/VEGFR axis
The impetus of targeting angiogenesis in order the curb tumor growth and progression has
already been recognized more than four decades ago (Folkman, 1971). Fig. 5 below depicts the various
routes where antibodies could be used to target the VEGF/VEGFR axis. The monoclonal antibody
bevacizumab (Avastin), a potent inhibitor of the ligand VEGF, is now deployed in a plethora of different
diseases, including kidney cancer, metastatic breast cancer (Miller et al., 2007) and advanced non-small cell
lung cancer (NSCLC) (Sandler et al., 2006), in combination with chemotherapy or immunotherapy (Bagri,
Kouros-Mehr, Leong, & Plowman, 2010). Other antibodies directed towards the receptor arm of the axis
have also been reported, and these antibodies target the ligand-binding domains of receptors VEGFR-2
(Witte et al.,  1998) and VEGFR-3 (Persaud et al.,  2004). Of note, the phase I dose escalation study of the
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VEGFR-3 inhibitor IMC-3C5 has recently been completed, for patients with advanced solid tumors
refractory to conventional therapy or where no standard therapy could be envisaged
(http://clinicaltrials.gov/ct2/show/NCT01288989). Ramucirumab, an inhibitor of VEGFR-2 that also targets
the ligand-binding domain, has recently been reported in a completed phase 3 trial, where it conferred
survival benefits among patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
even when administered as a monotherapy (Fuchs et al., 2014).
Figure 5. The inhibition of the VEGF/VEGFR axis.
Antibodies targeting the ligand arm or the receptor arm of the VEGF/VEGFR signaling axis are illustrated, as
well as soluble ligand traps that sequester ligands from binding and activating their cognate receptors. The
Tie1 and Tie2 receptor tyrosine kinases of another receptor family are also represented. Ab denotes
antibodies; Ab* denotes the subset of antibodies inhibiting receptor dimerization. TKI refers to tyrosine
kinase inhibitors; Ang2 refers to angiopoietin-2 and Pb refers to a peptibody fusion protein against Ang2.
Source: (Alitalo, 2011).
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Recent work has expanded the inhibition of the VEGF/VEGFR axis with modalities other than
inhibiting ligand binding and using soluble ligand traps, as exemplified by the use of a monoclonal antibody
2E11 that recognizes a conformational epitope present at least in part in the immunoglobulin homology
domain 5 (D5) of VEGFR-3, the domain important for receptor dimerization. This murine monoclonal did
not recognize the ligand binding domain D1-D3, and thus could inhibit VEGFR-3 signaling independent of
ligand concentration (ie. even at high ligand concentrations where receptor-blocking antibodies would have
been outcompeted). Indeed, this antibody inhibited VEGFR-3 heterodimerization with VEGFR-2 and
signaling from VEGFR-3 homodimerization. More importantly, it exhibited a synergistic effect in inhibiting
endothelial sprouting and vascular morphogenesis when used in conjunction with antibodies that inhibit
ligand binding (Tvorogov et al., 2010). A graphical representation of the inhibition principle of this antibody
is shown in Fig. 6 below.
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Figure 6. Combinatorial use of ligand-binding inhibitors and receptor dimerization inhibitors.
Antibodies that inhibit ligand binding (shown in blue) are capable of inhibiting receptor homo- or
heterodimerization (and their downstream signaling events), but this effect is severely compromised at
high ligand concentrations. Antibodies targeted to the dimerization domain (shown in red) could also
inhibit receptor homo- or heterodimerization, and remain effective even at high ligand concentrations. The
coupled use of antibodies employing both strategies of receptor inhibition serves as a synergistic platform
in antagonizing the VEGF/VEGFR signaling cascade. Source: (Tvorogov et al., 2010).
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1.4 Background
The background of this Master’s thesis is based on the work already published (Tvorogov et
al., 2010) and is an extension of the same principle of inhibiting VEGFR-3 homo- or heterodimerization, to
be used in a synergistic fashion with existing antibodies that inhibit ligand binding in antagonizing the
VEGF/VEGFR axis, particularly VEGFR-3-mediated signaling. Because the existing 2E11 monoclonal is of
murine origin, and therefore implicates issues with immunogenicity such as HAMA, human antibodies
would present as better therapeutics for this endeavor. One method of generating such human antibodies
is to survey artificial human antibody phage display libraries for potential binders towards VEGFR-3
dimerization epitope.
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2. AIM OF THE STUDY
The aims of this Master’s thesis are:
1. To select human Fab antibody fragments targeted to VEGFR-3 dimerization domain by surveying
the artificial human antibody phage display library
2. To assess the robustness and performance of the antibody phage display library as a valuable
source of specific antibody fragments
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3. MATERIALS and METHODS
3.1 Refreshment of antibody phage display library (F-library)
The antibody phage display library (kind gift of Dr. Fellouse) was refreshed from glycerol
stocks by transducing logarithmic-phase (OD600nm = 0.5) TG1 E.coli in 1L liquid culture of 2xYT media, at a
multiplicity  of  infection  (MOI)  of  0.1  for  1.5h  at  +37°C  at  180rpm.  Ampicillin  was  added  to  a  final
concentration of 100µg/ml for the selection of phage-transduced bacteria and the culture was maintained
for  an  additional  1h.  M13KO7  helper  phages  (kind  gift  of  Next  Biomed  Technologies  Oy)  were  then
introduced at an MOI of 10 for the rescue of phage progeny, wherein the bacterial culture was maintained
for 2h at +37°C at 180rpm. Kanamycin was then added to a final concentration of 70µg/ml and the culture
was maintained overnight at +37°C at 180rpm. Bacteria were pelleted by centrifugation of the overnight
culture at 5,000rpm (4,080g) for 30mins at +4°C on a Sorvall  RC 5B Plus centrifuge. The phage-containing
supernatant  was filtered through a  0.45µm sterile  filter  unit  (Millipore)  to  remove any bacterial  debris.  1
volume  of  polyethylene  glycol  6000  (PEG  6000,  Fluka  Chemika)  containing  2.5M  NaCl  (VWR)  was  then
added to 4 volumes of the phage-containing supernatant for phage precipitation, and incubated on ice for
1h. Phages were pelleted by centrifugation at 10,000rpm (16,300g) for 30mins at +4°C, then resuspended
in PBS, and debris was removed by centrifugation at 5,000rpm (2,300g) for 20mins at +4°C using a table-top
microcentrifuge (Eppendorf 5415 R). Finally, phages were ready for infectious titer determination.
3.2 Determination of phage infectious titer
10-fold serial dilutions of the concentrated phage stock were made in PBS to a total volume
of 100µl, of which 10µl of the diluted phage preparation was used to transduce 200µl logarithmic-phase
TG1 for 30mins at +37°C without shaking. 100µl of transduced bacteria were then plated onto Luria-Bertani
(LB) plates containing 100µg/ml ampicillin as a supplement and incubated overnight at +37°C. Infectious
titer was determined using the colony count assay where titer = Number of colonies x Dilution factor x 2 x
1000µl/ml x 1/Volume of plated cells (ie. 100µl), therefore expressed as colony-forming units/ml (cfu/ml).
Using  this  equation  the  infectious  titer  of  the  refreshed  naïve  library  was  determined  to  be  1.7  x  1013
cfu/ml.
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3.3 Affinity selection with VEGFR-3 fragments
Biopanning of the antibody phage display library was performed against VEGFR-3 fragments
to identify any VEGFR-3-specific antibody fragments. The VEGFR-3 antigens were kindly provided by Dr.
Veli-Matti Leppänen. Affinity selection was accomplished using 2 main strategies. The first strategy of
employed a biotinylated version of VEGFR-3 domains 4 and 5 (b-R3D45) as the capture antigen. Specifically,
10µl of streptavidin-coated magnetic beads (Dynabeads M-280, Invitrogen) were washed in PBS according
to the manufacturer’s instructions and incubated with 20µg of b-R3D45 in a total reaction volume of 200µl
in PBS. The mixture was incubated at room temperature for 30mins with mixing by rotation. The control
(mock) experiment involved a parallel set of 10µl beads incubated without the antigen. Beads were then
magnetically separated and washed in accordance with manufacturer’s instructions and transducing phage
units were introduced, in a total reaction volume of 1ml in blocking buffer PBS containing 5% non-fat milk.
The incubation was allowed to  proceed overnight  at  +4°C with  mixing by  rotation.  Beads were washed 5
times in PBS and bound phages were released by trypsin elution, where 100µl of trypsin (Sigma) was added
and  the  reaction  incubated  for  1h  at  room  temperature.  The  eluate  was  used  to  transduce  10ml  of  TG1
bacteria  in  exponential  growth  phase  for  1h  at  +37°C  at  180rpm.  300µl  of  this  culture  was  removed  to
prepare 10-fold serial dilutions in 2xYT media. For output titer determination, 100µl of each diluted
preparation was plated onto Luria-Bertani (LB) plates containing 100µg/ml ampicillin as a supplement and
incubated overnight at +37°C. The output titer was calculated as follows: Output titer = Number of colonies
x Dilution factor x 1/Volume of plated cells (ie. 100µl) x 1000µl/ml, therefore expressed as cfu/ml. The b-
R3D45-selected phage pool was to be amplified. Ampicillin was added to a final concentration of 100µg/ml
and the culture was propagated for a further 1h. Helper phages were introduced as above for the rescue of
progeny phage and the culture was propagated overnight with selection using 70µg/ml kanamycin as
described above. Phages were harvested and precipitated as described above, resuspended in PBS and
used for subsequent rounds of affinity selection.
The second strategy of affinity selection featured VEGFR-3 domains 1 through 7 (R3D17), the
extracellular domain of VEGFR-3, as the capture antigen. Specifically, the antigen R3D17 was passively-
coated onto 6-well  plates  (Greiner  CELLSTAR)  at  a  concentration of  10µg/ml  overnight  at  +4°C,  in  a  total
volume of 1ml in PBS. Control wells were incubated in PBS without antigen. Wells were washed 3 times in
PBS and blocked for 1.5h at room temperature with PBS containing 5% non-fat milk to prevent unspecific
binding. Wells were washed as above and phages were incubated in a total volume of 1ml in PBS containing
5% non-fat milk for 1h at room temperature with rotation on a platform at 90rpm. Wells were washed 5
times in PBS containing 0.1% Tween-20 (PBST) to remove unbound phage. 2ml of logarithmic-phase TG1
bacteria was then added for transduction by bound phage without elution, 30mins at +37°C without
shaking.  After  transduction,  a  200µl  aliquot  was  removed  for  10-fold  serial  dilution  in  2xYT  and  100µl  of
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each dilution was plated for output titer determination. The output titer was calculated based on the same
equation as above. The remaining 1.8ml of transduced bacteria was combined with 48ml of logarithmic-
phase TG1 bacteria for increased culture volume and subsequent phage recovery. The 50ml culture was
propagated for 30mins at +37°C at 180rpm. Ampicillin was added to a final concentration of 100µg/ml and
the culture was propagated for a further 1h. Helper phages were introduced as above and the culture was
propagated overnight with selection using 70µg/ml kanamycin as described above. Phages were harvested
and precipitated as described above, resuspended in PBS and used for subsequent rounds of affinity
selection.
3.4 Screening for positive clones by monoclonal phage ELISA
To identify VEGFR-3-specific antibody fragments, random colonies were selected from
enriched output titer plates for liquid culture in 2xYT media containing 100µg/ml ampicillin as a
supplement, either as 10ml cultures in 50ml tubes, or in 96-well plates (Nunc), the latter based on the
protocol as described by others (Lee et al., 2007). Phages were produced from individual phagemid clones
as a homogeneous preparation and subsequently screened using a monoclonal phage ELISA. The phage-
containing supernatant was precipitated and prepared as a concentrated stock for the case of 10ml
cultures or used directly without precipitation as a high-titer concentrated phage preparation was not
necessary for phage production from 96-well plates.
The monoclonal phage ELISA protocol was adapted from already published work (Lee et al.,
2007). 6-well plates (Nunc) were coated overnight at +4°C with 5µg/ml b-R3D45 or 2µg/ml R3D17 antigen
diluted  in  PBS  in  a  volume  of  100µl.  Wells  were  washed  3  times  in  PBS  and  blocked  with  250µl  of  PBS
containing 5% non-fat milk for 2h at room temperature, with rotation and mixing at 130rpm. Wells were
washed again for 3 times in PBS. In a separate 96-well plate, phage-containing supernatant of each clone
was diluted 1:4 in PBS containing 5% non-fat milk as the blocking buffer to a volume of 100µl and applied to
the wells washed above. Alternatively, precipitated concentrated phage stocks were used at 1:10 dilution in
blocking buffer. The incubation of the phages to allow binding to coated b-R3D45 or R3D17 was carried out
for  1h  at  room  temperature  with  rotation  at  90rpm.  Wells  were  washed  5  times  in  PBS  containing  0.1%
Tween-20 (PBST) and an additional 3 times in PBS to remove all unbound phage. Anti-M13 HRP-conjugate
mouse monoclonal antibody (GE Healthcare) was applied at 1:2000 dilution in PBS containing 5% non-fat
milk at a volume of 100µl, and incubated for 1h at room temperature with rotation at 90rpm. Wells were
washed  3  times  in  PBST  and  an  additional  3  times  in  PBS.  Finally,  100µl  ready-to-use  ABTS  substrate
(Invitrogen) was applied to the wells, incubated for 15-30mins at room temperature and the absorbance at
405nm was measured with a 96-well plate Multiskan EX spectrophotometer (ThermoLabsystems). Positive
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clones were defined as those which gave a signal of at least twice that of a negative control phagemid clone
selected from a control output titer plate (Moreland et al., 2012). The positive control was represented by
clone P4.1, whenever applicable. These clones were further analyzed and characterized by performing
plasmid minipreps (Qiagen) of the corresponding phagemid clones and sequencing using the sense primers
FLibF1 and AM126 for probing the light chain and heavy chain respectively.
3.5 Cloning of VEGFR3-specific Fab genes into pET12a expression vector
In order to perform subsequent functional studies, these newly identified phage-displayed
human antibody fragments specific to VEGFR-3 dimerization domain were introduced into a different
bacterial expression system for periplasmic expression. These human antibody fragments were to be
expressed as soluble proteins devoid of any phage component/pIII minor coat protein. The pET12a
expression vector was selected for this endeavor, to be used in conjunction with the BL21(DE3)pLysS strain
of E.coli. This pET12a vector had previously been engineered to contain a NotI site between its SalI site and
BamHI site. Phagemid DNAs of these individual unique clones were prepared using miniprep kits (Qiagen)
and their corresponding antibody genes PCR-amplified with the primers YSL01 and YSL02. The antisense
primer YSL02 also introduced a TAG stop codon just before and overlapping the NotI site. PCR was
performed using Phusion DNA polymerase in accordance with the manufacturer’s instructions on a G-
STORM GS482 thermal cycler (Gene Technologies). PCR products were analyzed on agarose gel
electrophoresis and purified with PCR product purification kit (Qiagen). Purified PCR products were then
digested with SalI and NotI (Fermentas), gel-purified (Qiagen gel purification kit) and ligated into similarly-
digested modified pET12a vector using T4 DNA ligase (Fermentas). Ligated products were transformed into
the XL1-Blue E.coli strain for plasmid DNA amplification and purification by miniprep kit (Qiagen). All newly
cloned pET12a constructs were sequenced verified with the sense primer FLibF1.
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3.6 Bacterial expression of human Fab antibody fragments
The BL21(DE3)pLysS strain of E.coli was used for periplasmic expression of the cloned human
antibody fragments in modified pET12a vector. Specifically, pET12a vectors containing the antibody inserts
were transformed into the above-mentioned E.coli strain. Quadruplicate colonies were picked per each
unique antibody clone to inoculate overnight 5ml starter cultures of Luria broth containing 100µg/ml
ampicillin as supplement. Overnight cultures were diluted to 100ml Luria broth containing 100µg/ml
ampicillin and grown to exponential phase at which point IPTG (Fermentas) was added to a final
concentration of 0.5mM. Cultures were propagated overnight at +37°C at 180rpm. Overnight cultures were
cleared by centrifugation at 5,000rpm (3,020g) for 30mins at +4°C, and the Fab-containing supernatants
filtered through a 0.45µm filter unit (Millipore) to remove any bacterial debris. These supernatants were
subsequently screened by Western blotting to validate the presence of expressed Fabs.
3.7 Western blot validation of expressed anti-VEGFR3 human Fabs
Western blotting was performed to confirm the expression of VEGFR3-specific human Fabs
via the FLAG epitope present C-terminal to the light chain antibody sequence. Filtered antibody-containing
supernatants  from  above  were  boiled  at  +95°C  for  5mins  in  1x  Laemmli  buffer  containing  β-
mecaptoethanol, then loaded onto and resolved by 12% polyacrylamide gel electrophoresis (PAGE).
Resolved fragments were transferred onto 0.2µm nitrocellulose membranes (Biorad) by semi-dry transfer
apparatus (Biorad Trans-Blot SD), and then blocked with PBS containing 5% non-fat milk for 1.5h at room
temperature with mixing by a table-top shaker. After 3 washes with PBS containing 0.05% Tween-20 (PBST),
the membranes were incubated with mouse anti-FLAG M2 antibody (Sigma) at 1:5000 dilution in PBS
containing 3% non-fat milk, overnight at +4°C with mixing by a table-top shaker. Membranes were washed
as above, and goat anti-mouse-IRDye680 secondary antibody (LI-COR Biosciences) was added at 1:2500
dilution in PBS containing 3% non-fat milk, and incubated for 1.5h at room temperature with mixing by a
table-top shaker. Membranes were washed as above, and analyzed on the Odyssey infrared analyzer (LI-
COR Biosciences).
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4. RESULTS
4.1 Affinity selection
4.1.1 Results of first series (P-series) of affinity selection experiments using b-R3D45
A total of 5 rounds of affinity selection (P-series) were performed using the biotinylated
capture  antigen  b-R3D45  via  the  first  strategy  (Fig.  7a).  In  the  first  round  of  selection,  P1,  6.8  x  1012
transducing phage units from the refreshed naïve library were introduced for binding to b-R3D45, which
through its biotin moiety had been immobilized on streptavidin-coated magnetic beads. This quantity of
phages fully represented the entire repertoire and diversity of the entire Fab antibody library whose size
had previously been empirically determined to be at about 3 x 1010 (refer to Fig. 4). The input and output
phage transducing units were determined by titration of transduced bacteria using the colony count assay
as described in Materials and Methods.
There was no overt enrichment of specific b-R3D45-binding clones, as the output titers of
both b-R3D45-selected phages and those from the control (mock panning) were of the same order of
magnitude (a modest enrichment of 1.3). This represented a canonical result of the first round of
biopanning, in which no specific binders would have been enriched at this early stage.
In the second round of affinity selection, P2, a total of 2.9 x 1012 phages amplified from the
first round were introduced for binding to the capture antigen b-R3D45. As with the case in the first round
of selection, there was not an outnumbering fold of b-R3D45-selected phages over the control, although
the enrichment factor had slightly increased from 1.3 to 3.0, suggesting that the phage pool might have
been tapered towards more specific clones. Interestingly, the output titer was markedly reduced as
compared to that obtained in the first round, differing by a few orders of magnitude. Nonetheless, as
enrichment was not envisaged at this stage of affinity selection, b-R3D45-selected phages were amplified
for the third round of selection.
In  the  third  round  of  affinity  selection,  P3,  1.14  x  1012 phages amplified from the second
round were introduced for binding to b-R3D45. For the first time, a dramatic enrichment of phages was
observed  with  the  capture  antigen  b-R3D45  as  compared  to  control.  There  was  a  more  than  200-fold
enrichment which strongly suggested that b-R3D45-specific clones have been enriched at this stage.
In the fourth round of affinity selection, P4, 2.3 x 1012 phages amplified from the third round
were introduced for binding to b-R3D45. The results of the fourth round recapitulated that observed in the
third.  A  more  than  200-fold  enrichment  of  b-R3D45-selected  phages  as  compared  to  control  was  again
observed.
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In the fifth round of affinity selection, P5, 2.88 x 1013 phages amplified from the fourth round
of selection were introduced for binding to b-R3D45. There was a more than 60-fold enrichment of b-
R3D45-selected phages as compared to control. To exclude the possibility that phages might have been
enriched towards the biotin moiety present in the biotinylated capture antigen b-R3D45, a control
biotinylated antigen, b-GST Hck SH3 (biotinylated GST-tagged SH3 domain of Hck), was also introduced as a
mock capture antigen for affinity selection done in parallel. Intuitively, this control capture antigen was not
expected to enrich for any phages at this stage of biopanning when the phage diversity has already been
primed towards R3D45-specific clones. Indeed, the b-R3D45-selected phages yielded an enrichment factor
of 64.8 over this mock antigen selection (data not shown), demonstrating that the enriched phages were
not  targeted towards  the biotin  moiety.  At  this  stage,  it  was  decided that  random clones  be selected for
further analysis of specificity by monoclonal phage ELISA and characterization by sequencing.
4.1.2 Results of second series (Q-series) of affinity selection experiments incorporating the
alternative biopanning strategy
In a bid to uncover more promising specific clones to VEGFR-3 dimerization domain, the
affinity selection strategy was modified such that b-R3D45 was no longer the only antigen choice in every
round of  selection.  To this  end,  the extracellular  domain of  VEGFR-3,  domains  1  through 7  (R3D17),  was
also selected as a capture antigen, to be used in an alternate fashion with b-R3D45. Because R3D17 was not
biotinylated, it was passively coated onto the plastic surfaces of a 6-well plate and used to select for phages
that bound to immobilized R3D17. The panning strategy was such that the first and third rounds (Q1 and
Q3) were performed as before, through the use of streptavidin magnetic beads; while the second and
fourth rounds (Q2 and Q4)  introduced the new R3D17 method (Fig.  7b).  A  total  of  4  rounds of  selection
were performed.
As the unique single clone P4.1 had already been uncovered in the previous series of
selection  experiments  by  this  stage  (refer  to  Results  3.2  below),  it  served  as  a  useful  tool  by  acting  as  a
positive control in this new panning strategy. In the first selection round Q1, 4 x 1012 phages of the
refreshed  naïve  library  and  1.2  x  1010 phages of the homogeneous positive control clone P4.1 were
introduced for selection with and without the capture antigen. Indeed, the positive control clone exhibited
a more than 200-fold enrichment over the control (mock) selection (data not shown) demonstrating an
exceptional binding towards b-R3D45 and its robustness for use as a positive control. With regards to the
naïve library, results in Q1 reflected a modest 4.9-fold excess of b-R3D45-selected phages over the control
(mock) selection, although any enrichment of specific clones at this first round of selection was not
expected.
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For  the  second  round  of  selection  Q2  wherein  the  R3D17  antigen  was  first  used,  1  x  1011
phages  amplified from the first  round Q1 and 6  x  109 phages of the homogeneous positive control clone
P4.1 were introduced for selection with and without the capture antigen. Similar to the results of Q1, there
was no enrichment of R3D17-specific phages at this stage, concurring with results derived from the
previous panning strategy where there was no enrichment after the first 2 rounds of selection. Again, in the
second round of panning Q2, there was an incredible enrichment of this positive control clone retained by
the  R3D17  antigen  over  the  control  surface  on  which  the  antigen  was  not  coated.  This  was  completely
within  expectation  as  it  was  known  that  this  clone  was  specific  to  b-R3D45  and  had  been  prepared  as  a
homogeneous preparation. A negative control clone represented by a homogeneous phage prepared from
a phagemid clone selected from a control  plate  was also  included in  the selection.  2  x  108 phages of this
negative control clone were introduced for affinity selection, but there was no enrichment of phages by
R3D17 over the control selection (enrichment factor of 1.1).
In  the  third  round  of  selection  Q3,  1.3  x  1012 phages amplified from the second round Q2
were introduced for selection by b-R3D45. Essentially, the third round of selection which reverted to the
use of b-R3D45 as the capture antigen was in principle the same as that performed previously (as in Q1 and
P-series experiments). It was rather surprising that there was no enrichment of b-R3D45-selected phages
over the control after 3 rounds of selection, which had already been evident in the previous P-series
selections (a more than 200-fold enrichment by this stage). Nevertheless, a final selection round using
immobilized R3D17 was performed.
In the fourth and final round of selection Q4, 2.2 x 1011 phages amplified from the third
round Q3 were introduced for selection by R3D17. With this alternate antigen-switching mode of affinity
selection, enrichment was finally observed after 4 rounds of selection, in particular up to 250-fold. Random
clones were selected after 4 rounds of panning for further characterization by monoclonal phage ELISA and
sequencing.
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(a) (b)
Antigen Input Output Enrichment Antigen Input Output Enrichment
b-R3D45 6.8 x 1012 6 x 106 1.3 b-R3D45 4.0 x 1012 3.5 x 107 4.9
Control (mock) 6.8 x 1012 4.6 x 106 - Control (mock) 4.0 x 1012 7.2 x 106 -
Input Output Enrichment Input Output Enrichment
b-R3D45 2.9 x 1012 6 x 103 3.0 R3D17 1.0 x 1011 > 6 x 103 N.A
Control (mock) 2.9 x 1012 2 x 103 - Control (mock) 1.0 x 1011 > 6 x 103 -
Input Output Enrichment Input Output Enrichment
b-R3D45 1.14 x 1012 4.5 x 106 236.8 b-R3D45 1.3 x 1012 4.4 x 105 1.0
Control (mock) 1.14 x 1012 1.9 x 104 - Control (mock) 1.3 x 1012 4.3 x 105 -
Input Output Enrichment Input Output Enrichment
b-R3D45 2.3 x 1012 4 x 106 235.2 R3D17 2.2 x 1011 5.0 x 106 250.0
Control (mock) 2.3 x 1012 1.7 x 104 - Control (mock) 2.2 x 1011 2.0 x 104 -
Input Output Enrichment
b-R3D45 2.88 x 1013 3.5 x 107 62.5
Control (mock) 2.88 x 1013 5.6 x 105 -
P5
P4 Q4
P1 Q1
Q2
Q3
P2
P3
Figure 7. Affinity selections for binders targeted to VEGFR-3 dimerization domain.
(a) Results after 5 rounds of selection with b-R3D45 (P1 to P5) and (b) after 4 rounds of selection with the
alternating use of b-R3D45 (Q1 and Q3) and R3D17 (highlighted in purple) (Q2 and Q4). Control (mock)
refers to selections without the antigen. Input (and output) refers to the quantity of input (and output)
transducing phage units. Enrichment is calculated as the ratio of outputs between antigen selections and
control (mock) selections.
4.2 Screening for positive clones by monoclonal phage ELISA and analysis by sequencing
4.2.1 Characterization of clones after P-series of affinity selections
Individual unique phagemid clones were randomly selected from the output titer plates of
P4 and P5, the fourth and fifth rounds of affinity selection that used the first strategy, and subsequently
generated as homogeneous phage preparations. 12 colonies each from P4 and P5 were selected and
propagated in liquid culture, and it was hypothesized that clones from P4 may exhibit a certain degree of
variability and diversity while those of P5 would probably be saturated with 1 or 2 high-performing clones.
These clones were sequenced with the forward primer FLibF1 which probed the randomized CDR-L3 and
the forward primer AM126 which probed the randomized CDR-H1, CDR-H2 and CDR-H3. Unexpectedly, the
sequencing results revealed only one unique clone (P4.1), and by P4 this clone had already saturated the
pool (Fig. 8a). Expectedly, when performed on monoclonal phage ELISA, this clone exhibited convincing
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positive results as reflected by an almost instantaneous color change upon substrate addition. This
indicated that in the affinity selection experiments 4 rounds were sufficient to isolate one single binder and
perhaps there might be more diversity within the pool at the earlier P3 stage. Indeed, when the
experiments were repeated and 12 clones (P3.1 to P3.12) were randomly selected and sequenced after the
third round of panning, a certain degree of variability and diversity was observed (Fig. 8a), as demonstrated
by the presence of 7 different clones. When subsequently screened by monoclonal phage ELISA, 5 of these
7 newly characterized clones yielded positive results. Of note, one clone (P3.3), though represented in 5
copies (out of 12 random selections) and seemingly had been enriched as a specific binder, yielded only
weakly  positive  results  in  monoclonal  phage  ELISA,  if  at  all.  The  other  clone  clone  which  did  not  give
positive results was clone P3.11, recovered in 1 copy. Because these clones were randomly selected to be
sequenced before being screened by ELISA to be positive, it was possible for nonspecific clones to have
been included, such as in the case of P3.11.
In order to screen for positive clones at a much larger scale, a higher-throughput method
was established such that 96 random clones could be screened in a single run. Therefore, 92 random clones
(controls excluded) from this P3 selection round were also selected for propagation in liquid culture and
homogeneous phage supernatant production. These phage supernatants were screened in monoclonal
phage ELISA without duplicates which would otherwise decrease the number of screened colonies by half.
8  out  of  the 92 clones  screened yielded promising results  on monoclonal  phage ELISA,  all  of  which were
sequenced and characterized (Fig. 8b). In addition, a random clone (3A4) that gave negative results on the
monoclonal phage ELISA was also sequenced to query which background nonspecific clone remained in the
phage pool after 3 rounds of selection. 2 positive control samples (independently selected clone P4.1
phagemid colonies) and 2 negative control samples (independently selected phagemid colonies from
control output titer plates) were included. Multiple positive and negative control samples were used to
minimize  random  errors  arising  from  phage  titer  variation.  Interestingly,  this  clone  3A4  was  identical  to
clone P3.3 which had previously been characterized. This result strongly indicated and added weight to the
speculation that clone P3.3 was indeed a nonspecific background member of the otherwise enriched phage
pool. Intriguingly, 2 new clones were characterized (clones 3H2 and 3H4), which would almost certainly be
missed had this new screening method not been established. Clone 3G11 surfaced again, identical to
previously described clone P3.6, and was recovered in 4 copies. This clone was unmistakably a specific
binder as it had been independently produced and validated by ELISA.
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(a)
Clone
91 92 93 94 94
a
94
b
94
c
95 96 29 30 31 32 33 34 50 51 52 52
a
53 54 55 56 57 58 94 95 96 97 98 99 10
0
10
0a
10
0b
10
0c
10
0d
10
0e
10
0f
10
0g
10
0h
10
0i
10
0j
10
0k
10
0l
10
1 Frequency of recovery
P4.1 W G G Y Y A - P I I Y S S S I S I Y P Y Y G Y T Y R S Y Y - - - - - - - - - - - - - A I D 24 / 24
P3.3 Y Y V - - - - P F I Y Y S S M S I Y P S Y G S T Y R T V R G S K K P Y F S G W - - - A M D 5 / 12
P3.6 Y Y V Y - - - P I I Y S Y Y M S I S P Y S G S T Y R Y W Y V - - - - - - - - - - - - G M D 2 / 12
P3.1 F H S - - - - P F L Y Y S Y M S I Y S S S G Y T S R G S W P Y S Y S Y G G W W S S S G M D 1 / 12
P3.2 S S V G H S - P I I Y S S S M S I S S Y Y G S T Y R V S H G A Y Y Y S Y - - - - - - G M D 1 / 12
P3.5 Y Y H - - - - P F L Y S S S I S I Y P S Y G S T Y R T V R G S K K P Y F S G W - - - A M D 1 / 12
P3.7 G H W - - - - L I L Y S S S I Y I Y P Y S G Y T Y R Y Y G W W Y - - - - - - - - - - A L D 1 / 12
P3.11 Y Y V - - - - P F I Y S S S M S I Y S S Y G Y T Y R T V R G S K K P Y F S G W - - - A M D 1 / 12
(b)
3G11 Y Y V Y - - - P I I Y S Y Y M S I S P Y S G S T Y R Y W Y V - - - - - - - - - - - - G M D 4 / 9
3H2 W G G S Y A - P I I Y S S S M S I Y P Y Y G Y T Y R S Y S - - - - - - - - - - - - - A I D 2 / 9
3H4 Y F W - - - - L I I Y S Y S M S I S P Y S G S T Y R Y W W P - - - - - - - - - - - - G F D 2 / 9
3A4 Y Y V - - - - P F I Y Y S S M S I Y P S Y G S T Y R T V R G S K K P Y F S G W - - - A M D 1 / 9
(c)
4F1 W G G Y Y A - P I I Y S S S I S I Y P Y Y G Y T Y R S Y Y - - - - - - - - - - - - - A I D 7 / 19
4G1 P S W A S - - P F I Y S S S M S I Y P Y Y G Y T Y R Y W W Y G - - - - - - - - - - - A I D 6 / 19
4D7 V Y A G P G S P I I S S Y S M Y I S P Y Y S Y T Y R P W G A W Y - - - - - - - - - - A L D 5 / 19
4A2 W S Y P S G S P I I Y S S S I S I Y P Y Y G Y T Y R S Y Y - - - - - - - - - - - - - A I D 1 / 19
CDR-L3 CDR-H1 CDR-H2 CDR-H3
Figure 8. Characterization and CDR sequences of VEGFR-3-selected Fabs.
Positions indicated are based on the nomenclature described by Kabat et al. As previously described (Fellouse et al., 2007), the following residues are
highlighted – Tyr, yellow; Ser, red; Gly, green. Invariant positions in the library design are highlighted in grey, while gaps in alignment are represented by
dashes. (a) P4.1, the dominant single clone (highlighted in orange) after 4 and 5 rounds of selection with b-R3D45. In addition, 12 clones were randomly
selected for sequencing after 3 rounds of selection with the same antigen (before screening by monoclonal phage ELISA). (b) Characterization of all 8
positive clones and 1 negative clone (3A4) after screening by monoclonal phage ELISA (total 9 samples). Clones were derived after 3 rounds of selection with
b-R3D45 using the first strategy. Clones highlighted in purple are identical to each other; as is the case for clones highlighted in blue. (c) Characterization of
19 random positive clones after screening by monoclonal phage ELISA (total 91 positive samples). Clones were derived after 4 rounds of selection using the
second strategy that alternated between the use of antigens b-R3D45 and R3D17. Clones highlighted in orange are identical to each other.
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4.2.2 Characterization of clones after Q-series of affinity selections
From  the  Q-series  of  affinity  selection  experiments  that  employed  the  second  strategy  in
which the 2 capture antigens b-R3D45 and R3D17 were alternately used, 91 random clones (controls
excluded) were selected from Q4, the fourth round of selection, in the same fashion as previously
performed. These were also propagated in liquid culture in a 96-well plate format and produced as
individual homogeneous phage supernatant. Remarkably, all 91 clones screened showed positive results
(Fig. 9). It was not known at this stage if the pool had been already dominated by one or few clones, or if
there remained a certain degree of diversity. Given that all clones were positive, 19 random clones were
sequenced and characterized (Fig. 8c). Multiple positive and negative control samples were included, based
on the same principle as above.
The majority of these newly sequenced clones (clone 4F1, 7 out of 19) were the exact clone
as the positive control P4.1 that had previously been identified. However, there were also 3 new clones
that were not characterized before (clones 4G1, 4D7 and 4A2). In particular, clone 4G1 was represented in
6  copies;  clone  4D7  in  5  copies;  while  clone  4A2  was  represented  only  in  1  copy.  It  would  appear  that
clones 4G1 and 4D7, being recovered at higher frequency, may represent ‘fitter’ clones as compared to
clone 4A2. It is noteworthy, however, that clone 4A2 exhibited a striking resemblance to the positive
control clone P4.1, differing only in their CDR-L3 (identical CDR-H1, CDR-H2 and CDR-H3). It was also
observed that the Q4 heterogeneous phage pool was somewhat different from that where the previous
clones were characterized (P3 pool: P3.1 to P3.12; 3G11 to 3A4).
In summary, a total of 13 individual unique clones were enriched by b-R3D45 and R3D17
selection and sequence identified. With the exclusion of clones P3.3 and P3.11, these 11 clones, namely
P4.1, P3.1, P3.2, P3.5, P3.7, 3G11, 3H2, 3H4, 4G1, 4D7 and 4A2, proved to be interesting candidates to be
produced as human antibody fragments free of phage-derived material and further analyzed in functional
studies. Since clone P3.3 was enriched for reasons not fully understood, it was also selected for subsequent
cloning experiments as a non-VEGFR-3-specific negative control. Clone 4F1, a duplicate of the same clone
as P4.1, was also selected for cloning.
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Figure 9. Monoclonal phage ELISA screen for positive clones.
91 randomly-selected clones were screened after 4 rounds of selection which incorporated the second
strategy (Q4), using ELISA with immobilized R3D17 as antigen. 19 individual clones selected for sequencing
are  shown  in  orange.  The  2  positive  controls  and  3  negative  controls  are  shown  in  red  and  blue
respectively.
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4.3 Cloning of selected antibody genes into pET12a expression vector
Fig. 10 below shows representative results from clone 4D7 of PCR experiments where the
Fab antibody genes were amplified from the phagemid vector using the primers YSL01 and YSL02. To
elucidate the optimal annealing temperature, PCR reactions were carried out with a temperature gradient
from +60°C to  +72°C (lanes  2  to  7).  In  all  lanes,  the 1.7kb PCR product  was amplified demonstrating that
even the lowest annealing temperature tested (+60°C) was a viable annealing temperature. Since no
nonspecific products were formed at this temperature, it was standardized for subsequent PCR
experiments for the other clones. Lane 8 represents the negative control sample without phagemid DNA
template.
Figure 10. Agarose gel electrophoresis analysis of PCR-amplified Fab antibody gene.
The Fab antibody gene encoded by each unique phagemid clone is to be amplified by primers YSL01 and
YSL02 and subsequently introduced into the modified pET12a vector for Fab expression. Results for clone
4D7 are shown, with a temperature gradient for annealing temperature being tested from +60°C to +72°C.
Lane 1: GeneRulerTM 1kb DNA ladder  (Thermo Scientific);  Lanes  2  to  7:  1.7kb PCR product  containing Fab
antibody gene with annealing temperature gradient from +60°C (lane 2) to +72°C (lane 7); Lane 8: Negative
control without phagemid DNA template.
1.5kb
2kb
1              2               3               4               5               6               7               8
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4.4 Validation of expressed human Fabs by Western blot
Fig. 11 below shows representative western blot results from clones 3H2 and 4G1, detected
by probing the FLAG epitope C’ of the light chain antibody sequence. Because of inter-individual differences
between the colonies with regards to their propensity to express human Fabs, quadruplicates were picked
per each unique Fab clone, hereafter referred to as a, b, c and d (eg. 3H2a, 3H2b, 3H2c).
The Fab human antibody fragments were expressed and their antibody light chains detected
as proteins of approximate 25kDa (heavy chains were dissociated due to reducing conditions with β-
mecaptoethanol that disrupted the disulphide linkages). As demonstrated below, all quadruplicate colonies
of both clones 3H2 and 4G1 were able to express the desired antibody fragments, albeit to a different
extent, reiterating the argument for inter-individual differences in protein expression. This strongly
suggested, at least, that the 3H2 clone bacterial supernatant contained a higher concentration of human
Fabs as compared to that of the 4G1 clone. The previously expressed Fab of clone P4.1 was used as a
positive control in lane 2.
Figure 11. Anti-FLAG epitope Western blot for validation of expressed human Fabs.
Bacterial expression of human Fabs were confirmed by probing the FLAG epitope tag C’ of the antibody
light chain sequence. The antibody light chains were detected as proteins of approximately 25kDa.
Representative results are shown for clones 3H2 and 4G1 (in quadruplicates) with a previously validated
clone P4.1 as positive control. Lane 1: ColorPlusTM Prestained protein ladder, broad-range (10-230 kDa)
Clone
P4.1
Clone
3H2
Clone
4G1
  a             b             c             d             a              b             c             d
25 kDa
1             2              3              4               5               6              7               8               9              10
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(New England BioLabs); Lane 2: Clone P4.1, positive control; Lanes 3 to 6: Clone 3H2 (a to d); Lanes 7 to 10:
Clone 4G1 (a to d).
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5. DISCUSSION
5.1 Selection of VEGFR-3 dimerization domain-specific Fabs and their characteristics
The selection of a plethora of VEGFR-3 dimerization domain-specific binders from this
human antibody fragment library F-Library has attested to its performance and value as a rich resource for
isolating desired immunoproteins against a diverse range of antigens (Fellouse et al., 2007).
Remarkably, the two strategies of affinity selection enriched for antibody clones which are
distinctly different from one another, comparing clones of Fig. 8a and b to those of Fig. 8c (excluding clone
P4.1). The first series of selection experiments were based solely on b-R3D45 immobilized on streptavidin
magnetic beads and selection was performed only in mobile phase; while the second series alternated
between b-R3D45 selection in mobile phase and R3D17 selection in solid phase. Though R3D17 would in
theory encompass the entire sequence found on b-R3D45, it is arguable that the two antigens are not
identical, especially within the context of the selection conditions in which certain epitopes may be masked
or disproportionately represented. Therefore, in the selections that employed the second strategy the
phage pool might have been subjected to a different conformation-specific selection pressure as compared
to the phage pool present in selections that adopted only the first strategy. Therefore, the isolation of
clones that differ significantly from each other may accrue, at least in part, from antigen-restricted surface
determinants that are non-identical between b-R3D45 and R3D17, eg. clone 3H4 vs. 4D7.
Upon closer scrutiny of the characterized clones, numerous interesting points are noted.
First, the library design was such that the CDR-L3 was randomized with loops containing 4-6 residues at
positions 91-94 (refer to library design in Fig. 4). However, clones 4D7 and 4A2 proved otherwise by having
7 residues at these positions. Tipping the scale to the other side, several clones revealed short sequences at
these positions by having only 3 residues, for example clones P3.1, P3.5 and 3H2, among others. In a similar
fashion, the CDR-H3 was constructed such that positions 95-100a were randomized with loops between 6
and 17 residues. Yet, results show that several different clones harbored short sequences at these
positions, ranging from 3-5 residues, although long CDR-H3 sequences do not preclude interaction and
binding to our VEGFR-3 antigens, as exemplified by clone P3.1 that exhibited 17 residues at these positions,
the longest possible loop length. This indicates that the library may have been much more diverse than
initially thought.
Second, for both CDR-L3 and CDR-H3 where the greatest randomization was imbued, there is
a resounding high frequency of Tyr (Y), Ser (S) and Gly (G) residues. This may not be entirely surprising, at
least for the CDR-H3, as the library design had been biased towards these 3 residues. Also, this result is
consistent with the notion and observation that naturally occurring antibodies indeed have their CDRs
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enriched with the residues Y and S (Fellouse et al., 2005). Serine residues (and also alanine) have been
reported to play an ancillary role by conferring conformational flexibility in tyrosine-dominated contact
interfaces with antigen (Fellouse, Wiesmann, & Sidhu, 2004; Fellouse, Barthelemy, Kelley, & Sidhu, 2006).
Intriguingly, some residues surfaced at higher frequencies than would be predicted, such as Trp (W), Val
(V), His (H), Phe (F), Ala (A) and Pro (P), yet other residues such as Leu (L),  Ile (I)  and Met (M), as well as
negatively charged Glu (E) and Asp (D) never once surfaced (unless dictated by library design at predefined
positions), as if these latter-mentioned residues were omitted from the permitted amino acid choice. The
high incidence of aromatic residues such as Y, W and F may translate to the speculation that these residues
are responsible for dictating hydrophobic interactions within the binding cleft (the Fab:VEGFR-3 interface).
Third, although some of the characterized clones seem to be totally unrelated to each other,
there are few which exhibited immense similarity. For example, clone P4.1 is almost identical to clone 3H2
with only 1 amino acid difference each in CDR-L3, -H1 and -H3. In addition, the CDR-H2 is common between
clones P4.1 and 4G1, both of which being high-frequency clones of Q4, and is also present on clones 3H2
and 4A2, suggesting that this string of residues may play a role in specificity. Amazingly, clones P4.1 and
4A2 bear identical CDR-H1, -H2 and -H3, but their CDR-L3 are distinct from each other.
Clones P3.3 and P3.5 also bear an uncanny resemblance to each other, with only 4 residues
being  different  (1  in  CDR-L3;  3  in  CDR-H1).  However,  P3.5  exhibited  a  positive  signal  on  phage  ELISA
whereas P3.3 did not (weak at best), despite the latter whose several copies of the same clone had been
tested. It may be surmised that clone P3.3 was able to perform and be retained within the phage pool upon
subsequent rounds of selection by means other than b-R3D45-directed specificity.
Interestingly, clone 4G1 (represented in 6 copies) reflected slightly weaker ELISA signals in
general  when  compared  to  clones  4F1  and  4D7,  although  this  does  not  necessarily  translate  to  weaker
affinity. As the monoclonal phage ELISA screen employed phage-containing supernatant whose titer had
not been pre-determined and normalized between the samples, variations in phage titer may account for
differences in ELISA signals, at least in part, although it was reasoned that since these phage supernatants
were produced as individual homogeneous preparations, specific binders would render convincingly
positive signals even when tested at higher dilutions (ie. even if titer is low).
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5.2 Modulation of the affinity selection strategy
The first round of affinity selection is the most critical stage during the selection process, as
any specific binders lost would never be recovered in the subsequently amplified phage pools. Therefore,
despite the phage pool being highly diverse and saturated with nonspecific clones even after the first
selection round, specific clones that are retained within the phage pool, though seemingly outnumbered in
the beginning, would easily be enriched upon succeeding selection rounds. The use of a higher antigen
concentration in the first selection round as compared to succeeding rounds, which ensures the adequacy
of binding sites, therefore represents a good strategy to minimize the loss of any specific binders in the
early phase. This antigen concentration could be progressively tapered (lowered) upon each successive
selection round to mimic a selection pressure, by exposing the enriched phage pool to a progressively
limited binding surface, thus driving the enrichment of phages that exhibit a more favorable binding kinetic
profile.
The use of b-R3D45 in solution phase during the first round of selection in both P-series and
Q-series affinity selection experiments constitutes a better strategy than the use of R3D17 passively
immobilized onto the plastic bottom of a 6-well plate, as the latter method may result in conformational
changes in the peptide and/or denaturation, thus severely compromising the abundance of binding sites or
even modify the antigenic epitopes to undesirable surfaces. Such corrupted surfaces may enrich for phages
that compete with phages that are truly targeted to the desired antigenic surfaces, and intrinsic differences
in growth properties between the different phages may further complicate the selection process.
Notwithstanding, this does not negate the fact that specific binders could be generated towards passively
coated antigens. Indeed, it remains to be verified if three to four rounds of selection using only the R3D17
antigen or performing selections that toggle between the two antigens with the first round using R3D17
would yield the same VEGFR-3-specific clones. Other parameters during the selection process could be
modulated to enrich for binders towards a desired profile, for example limiting the interaction time
between the amplified phage pool and the antigen after the first selection round, to select for binders that
are readily captured by the antigen, ie. clones with high on-rate constant kforward.
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5.3 Bacterial expression of human VEGFR-3-specific Fabs
The differences between the qradruplicate colonies within each unique Fab antibody clone in
the degree of Fab expression have already been demonstrated in the results of Fig. 11. Apart from the
inherent inter-individual differences, one technical reason that could account for the expression variability
may be the fact that IPTG induction was initiated at the exponential phase of bacterial growth, but because
induction was carried out for multiple samples simultaneously, it was virtually impossible to standardize
the growth conditions of all individual cultures such that the optical density was identical, which therefore
could translate to moderate or even significant differences in physiological conditions, growth and
expression yield. Other means of expression employ the elegant use of amber-suppressor E.coli supE
strains during the selection phase (eg. TG1, XL1-Blue MRF’ and DH5a F’), where the TAG codon at the end
of the antibody coding sequence encodes a glutamic acid instead of a stop codon hence displaying fusion
proteins; and non-amber-suppressor strains during Fab expression (eg. TOP10 F’, HB2151 and JS5), where
the TAG is recognized as a stop codon, hence enabling the expression of soluble Fabs (Qi et al., 2012).
5.4 Future prospects
5.4.1 Further development and characterization of the selected VEGFR-3 Fabs
To query the efficacy of these selected human Fabs in inhibiting VEGFR-3-mediated signaling
and how well they compare to the existing mouse monoclonal 2E11 in synergistic inhibition of VEGFR-3
signaling when used in conjunction with receptor blocking antibodies like 3C5, these newly described Fabs
are to be concentrated from bacterial supernatants for instance by ammonium sulphate precipitation
and/or purification by FLAG tag-specific affinity gels (or protein A affinity columns) and subjected to
subsequent functional analyses, such as the inhibition of VEGF-C ligand-induced BaF3 cell survival
(Tvorogov et al., 2010). Though Fabs serve as functional antibody domains which could elicit biological
effects such as inhibiting receptor dimerization, it is not fully understood if their smaller size in comparison
to  a  whole  antibody  may  limit  their  efficacy  in  this  context.  Importantly,  these  Fab  genes  could  also  be
cloned into expression vectors that permit the eukaryotic expression of whole human IgG antibodies that
contain the effector Fcγ domain eg. in cell lines such as NS0 myeloma of murine origin (Persaud et al., 2004)
(akin to ‘arming’ the Fab), which are not supported by prokaryotic expression systems like pET12a.
Another approach to assess the performance of these novel Fabs in comparison to the
existing murine 2E11 in terms of binding affinity towards the VEGFR-3 dimerization interface is to perform a
competitive ELISA, where different concentrations of each of these novel Fabs are applied to immobilized
antigen VEGFR-3 dimerization domain in the presence of a constant concentration of 2E11. The extent to
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which the novel Fabs would outcompete the binding of 2E11 to its target would elucidate information
regarding their relative affinities towards the antigen.
Further studies to interrogate the binding kinetics of these human VEGFR-3-specific Fabs
could be undertaken, by means such as the biolayer interferometry-based instrument where various
concentrations of the soluble Fabs are introduced to biotinylated antigen immobilized onto a streptavidin
biosensor surface, thus yielding a calibration curve from which the association rate constant ka, dissociation
rate constant kd and dissociation constant KD (kd/ka) could be derived (Zhang et al., 2012).
5.4.2 Phage display in relation to VEGF/VEGFR drug discovery in the future
The hunt for novel antiangiogenic therapeutics has been relentless, particularly with respect
to new targeting modalities such as that reported for the inhibition of VEGFR-3 dimerization interface.
Indeed, shortly after this description another study reported a fully human VEGFR-2 antibody 33C3 derived
from the XenoMouse technology. In a similar fashion, this antibody specifically targets domains 4-7 of
VEGFR-2, the extracellular portion of the receptor implicated in receptor dimerization but not ligand
binding, and has been shown to mediate antiangiogenic effects independent of ligand concentration. Both
in-vitro and in-vivo models also demonstrated its efficacy in suppressing angiogenesis (Kendrew et al.,
2011).
The use of phage display to mine antibodies against other targets of the VEGF/VEGFR axis
has been described, an example of which targeted the ligand arm of the axis, where a fully human
monoclonal antibody fragment against human VEGF-C inhibited the ligand from binding to its receptors
VEGFR-2 and VEGFR-3 (Rinderknecht, Villa, Ballmer-Hofer, Neri, & Detmar, 2010). Another report
generated a fully human scFv fragment directed against VEGFR-2 which inhibited VEGF ligand-induced
human umbilical vein endothelial cell (HUVEC) proliferation (Zhang et al., 2012).
With the advent of single-domain antibody fragments (also known as nanobodies, VHH) that
originated from the discovery of camelid heavy chain-only antibodies (Hamers-Casterman et al., 1993), it is
of great interest to know if such minimalistic antibody domains could be isolated from phage-displayed
immune libraries surveyed against antigens such as VEGFR-3, and more importantly if such immunoproteins
could inhibit receptor activation and signaling by targeting the ligand-binding domain and/or the
dimerization interface. Indeed, a recent study has already described a nanobody targeted towards the
VEGF ligand that dose-dependently inhibited VEGF-stimulated HUVEC proliferation (Farajpour,
Rahbarizadeh, Kazemi, & Ahmadvand, 2014). The ease of expression of such nanobodies in prokaryotic and
eukaryotic hosts, as well as their capability of simultaneous inhibition of various ligands or their receptors,
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among others, position them as unparalleled drug candidates of the future (Roovers, van Dongen, & van
Bergen en Henegouwen, 2007; Van Bockstaele, Holz, & Revets, 2009).
Simultaneous targeting of VEGFR-2 and VEGFR-3 could work against tumor angiogenesis and
lymphangiogenesis, as evidenced in a breast cancer metastasis model (Roberts et al., 2006). However, as
these VEGF ligands and receptors govern intricate processes based on myriad ligand-receptor
combinations, as well as their expression on diverse cell types, the greater challenge of the future would be
finding the best method to home these novel specific therapeutics to the desired tumor locality.
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6. CONCLUSION
The human Fab phage display library F-library has presented as an invaluable tool in isolating
novel binders against the dimerization domain of VEGFR-3, and serves as a potential source of therapeutic
antibodies targeting receptor dimerization and inhibiting receptor activation in tumor angiogenesis and
lymphangiogenesis. As these novel antibody fragments are derived from an artificial human antibody
library, problems relating to immunogenicity through the use of murine antiangiogenic monoclonals could
be circumvented. Phage display technology remains a gold standard of display technology, and its
continued use, together with more modern display platforms of the likes of ribosome display and mRNA
display, will be entrusted with the task of uncovering novel and more potent therapeutics of the future,
addressing the plethora of human pathologies, particularly cancer.
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APPENDIX
Sequences of primers used in this Master’s Thesis:
Primer Sequence (5’ to 3’)
FLibF1 TTGATATCCAGATGACCCAGTC
AM126 GCTACAAACGCGTACGCTGAG
YSL01 ATGCGTCGACGATCCAGATGACCCAGTCCCCGA
YSL02 TTTTGCGGCCGCTATCCATGGCATGTGTGAGTTTTGTCACAAGATTTGGGCTCAACTTTCTTATCGACCTTGGTG
